GLP1_NEW
Semaglutide and bimagrumab 2.4 to 10 mg injection once weekly
BIMASEMA_SC_2p4-10MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD -1.06 (-13.21 to 10.00) | 0.53 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 83.10 (9.31 to 1718) | 0.88 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 43.43 (10.55 to 197) | 0.92 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 13.68 (4.65 to 37.85) | 0.73 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.17 (0.36 to 3.44) | 0.49 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.09 (0.23 to 4.03) | 0.65 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.18 (2.85 to 9.56) | 0.31 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.86 (1.47 to 10.17) | 0.53 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 4.81 (2.40 to 9.55) | 0.14 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.53 (0.96 to 6.50) | 0.41 |